Dr. Reddy's Laboratories has launched a sumatriptan autoinjector system (6 mg/0.5 ml), a treatment for migraine headaches, in the U.S. market.


Dr. Reddy's Laboratories, sumatriptan autoinjector system, treatment for migraine headaches, Imitrex STATdose Pen, generic equivalent, GlaxoSmithKline






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Dr. Reddy's releases generic of Imitrex STATdose Pen

February 26th, 2014

HYDERABAD, India – Dr. Reddy's Laboratories has launched a sumatriptan autoinjector system (6 mg/0.5 ml), a treatment for migraine headaches, in the U.S. market.

The company said Wednesday that its product, for subcutaneous use, is a generic equivalent of the Imitrex STATdose Pen (sumatriptan succinate 6 mg/0.5 ml) from GlaxoSmithKline.

The Dr. Reddy's sumatriptan injection is available in a carton containing two single-dose prefilled syringes.

For the year ended in December, the Imitrex STATdose Pen branded and generic products combined had U.S. sales of about $169 Million, according to IMS Health data reported by Dr. Reddy's.

 

Advertisement